Updates

Hutchison China Meditech - 2012 starts with a bang

April 2012

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

Solid full year figures from Hutchison driven by its Chinese consumer healthcare arm. Overall sales rose 24% to US$167m and operating profit was US$5.4m compared to a loss. The core Chinese healthcare division continued to grow helped by the increase in government spending on national healthcare. With its joint ventures proportionally consolidated, sales were up 16% to US$139m - all organic - thanks to leadership market shares in the Chinese cough-cold and cardiovascular drug markets. Its best seller, the cardiovascular prescription drug, She Xiang Bao Xin, saw blistering sales growth, up 32% to $79m. Being prescription it is also high margin compared to OTC remedies.The healthcare division's profitability fully ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

Advanced Computer Software - Net debt under Â£1m versus Â£25m six months ago

Global Energy Development - Applies new technology to bigger contract areas

Hutchison China Meditech -NÃ©stle deal for HMPL-004 drug (January 2013)

Hutchison China Meditech (September 2012)

Hutchison China Meditech (March 2012)

Hutchison China Meditech - Nets US$20m upfront collaboration payment from Astra Zeneca (January 2012)

Hutchison China Meditech - Broker says 600p sum of parts (September 2011)

Hutchison China Meditech - To distribute third party drugs (August 2011)

Hutchison China Meditech (April 2011)

Hutchison China Meditech - Pre-IPO funding ahead of NASDAQ float? (January 2011)

Hutchison China Meditech (October 2010)

Hutchison China Meditech - Out-licensing deal for lead product imminent (September 2010)

Hutchison China Meditech - Great secrecy shrouds R&D division (July 2010)

Hutchison China Meditech - 17 of 307 Chinese "essential medicines" (June 2010)

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X